Random de Comunicación Popular

Here’s What Caused Royalty Pharma’s Mixed Results in Q4

1 minuto de lectura

Most investors would view Royalty Pharma (NASDAQ: RPRX) as a disappointment. The company conducted its much-heralded initial public offering (IPO) last year. Shares ended 2020 up only 12%, well below the major market indexes. Its stock is in negative territory so far this year. RRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario